拉米夫定对慢性乙型肝炎患者可溶性HLA-1类分子含量的影响

The Change and Significance of Soluble HLA Class I Molecules Level in Treatment of Chronic Hepatitis B

目的:测定可溶性HLA-Ⅰ类分子的含量在慢性乙型肝炎治疗中的变化,并分析其意义。方法:将60例慢性乙型肝炎患者随机分为拉米夫定治疗组,甘利欣治疗组和拉米夫定加甘利欣联合治疗组每组均20例;血清可溶性HLA-Ⅰ类分子的含量用夹心ELISA方法测定。结果:治疗两个月,拉米夫定治疗组患者可溶性HIA-Ⅰ类分子的含量显著高于治疗前(P<0.01),甘利欣治疗组患者可溶性HLA-Ⅰ类分子的含量显著低于治疗前(P<0.05),联合治疗组患者可溶性HLA-Ⅰ类分子的含量与治疗前相比无显著变化;治疗4个月,3组患者可溶性HLA-Ⅰ类分子的含量均显著低于治疗前(P<0.01)。结论:可溶性HAL-Ⅰ类分子的含量反映了慢性乙型性肝炎治疗中患者免疫功能受到的调节。

Objective: To explore the change and significance of soluble HLA-I molecules level in treatment of chronic hepatitis B. Methods: CHB patients were randomly divided into three groups. One group were treated with Lamivudine, one group were treated with Diamminium glyrrihizinate and the other group were treated with both Lamivudine and Diammonium glyrrihixinate. Solubie HLA-I molecules wee detected with sandwich ELISA. Results: After two-month treatment, soluble HLA-I molecues ievel in patients of Lamivudine g...